Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Calidi Biotherapeutics ( (CLDI) ) just unveiled an update.
On September 16, 2025, Calidi Biotherapeutics‘ Board of Directors decided to eliminate the position of Chief Legal Officer, leading to the termination of Ms. Wendy Pizarro Campbell’s employment effective October 17, 2025. This move is part of the company’s ongoing efforts to streamline its senior leadership structure and improve operational efficiency. The termination was not due to any disagreements with Ms. Campbell, and she will receive severance pay and other benefits as per the separation agreement. Additionally, Ms. Campbell will enter a consulting agreement with the company for six months, starting October 18, 2025.
The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics, Inc. operates in the biotherapeutics industry, focusing on developing innovative treatments. The company is engaged in cost-reduction and operating-efficiency initiatives to align with its size, stage of development, and available resources.
Average Trading Volume: 1,593,379
Technical Sentiment Signal: Sell
Current Market Cap: $7.94M
See more insights into CLDI stock on TipRanks’ Stock Analysis page.